Picton Mahoney Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Picton Mahoney Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.86K	Hold	36	–	–	﹤0.01%	1033
2025 Q4	$1.79K	Hold	36	–	–	﹤0.01%	981
2025 Q3	$2K	Hold	36	–	–	﹤0.01%	843
2025 Q2	$1K	Sell	36 -558	-94%	-$17.9K	﹤0.01%	925
2025 Q1	$19K	Buy	594 +558	+1,550%	+$19.8K	﹤0.01%	590
2024 Q4	$1K	Hold	36	–	–	﹤0.01%	808
2024 Q3	$1K	Buy	+36	New	+$1.12K	﹤0.01%	795
2017 Q1	–	Sell	-6,400	Closed	-$161K	–	223
2016 Q4	$161K	Sell	6,400 -8,600	-57%	-$192K	0.01%	173
2016 Q3	$371K	Buy	15,000 +200	+1%	+$4.53K	0.02%	198
2016 Q2	$301K	Buy	+14,800	New	+$263K	0.02%	209
2016 Q1	–	Sell	-50,500	Closed	-$679K	–	357
2015 Q4	$679K	Sell	50,500 -24,800	-33%	-$384K	0.04%	186
2015 Q3	$1.06M	Buy	+75,300	New	+$1.4M	0.06%	168

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Picton Mahoney Asset Management's SUPN Position: Q1 2026 in Review

Picton Mahoney Asset Management held its Supernus Pharmaceuticals (SUPN) position steady in Q1 2026 at 36 shares worth $1.86K. The position accounts for ﹤0.01% of the portfolio, ranked #1033.

Picton Mahoney Asset Management first reported a position in SUPN in Q3 2015 and has held it in 12 quarters since. The position peaked at $1.06M in Q3 2015. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Picton Mahoney Asset Management held 36 shares of Supernus Pharmaceuticals worth $1.86K as of Q1 2026.
Picton Mahoney Asset Management left its Supernus Pharmaceuticals share count unchanged in Q1 2026.
Supernus Pharmaceuticals made up ﹤0.01% of Picton Mahoney Asset Management's portfolio in Q1 2026, its #1033 holding.
Picton Mahoney Asset Management first reported a position in Supernus Pharmaceuticals in Q3 2015 and has held it in 12 quarters since.
Picton Mahoney Asset Management's Supernus Pharmaceuticals position peaked at $1.06M in Q3 2015.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q1 2026, filed 13 May 2026.